Suchergebnisse
GitLab’s Price Recovery Gains Traction—Time to Get On Board?
GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Align Technology CFO: Global Growth, DSOs Offset North America Demand Pressure
Key Points
- Interested in Align Technology, Inc.? Here are five stocks we like better.
- Align Technology said international markets and North American DSOs are offsetting weakness in the U.S
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End
Key Points
- Interested in Alvotech? Here are five stocks we like better.
- Alvotech says it is at an “inflection point,” with management expecting five U.S. biosimilars on the market by year-end
Does InfuSystems Holdings (INFU) Have the Potential to Rally 62.61% as Wall Street Analysts Expect?
InfuSystems Holdings, Inc. (INFU) closed the last trading session at $9.12, gaining 1.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets
Wall Street Analysts Predict a 40.57% Upside in Omnicell (OMCL): Here's What You Should Know
Shares of Omnicell (OMCL) have gained 0.6% over the past four weeks to close the last trading session at $43.6, but there could still be a solid upside left in the stock if short-term price targets
Wall Street Analysts See a 27.97% Upside in Tecogen (TGEN): Can the Stock Really Move This High?
Tecogen Inc. (TGEN) closed the last trading session at $6.9, gaining 43.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know
Cencora (COR) closed the last trading session at $270.32, gaining 5.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street
D-Wave Unveils Fault-Tolerant Quantum Computing Plan: What's Ahead?
D-Wave Quantum QBTS or D-Wave is advancing its push toward commercial, fault-tolerant quantum computing. The company recently laid out a new gate-model roadmap, targeting 100 logical qubits capable
Chime Financial CEO Maps Growth Roadmap, $2.7B Revenue Target at Conference
Key Points
- Interested in Chime Financial, Inc.? Here are five stocks we like better.
- Chime CEO Chris Britt said the company is focused on building primary checking relationships with mainstream
Chime Financial CEO Maps Growth Roadmap, $2.7B Revenue Target at Conference
Chime Financial CEO Maps Growth Roadmap, $2.7B Revenue Target at Conference
BASF Bets on China Growth as Zhanjiang Site Targets €5 Billion in Sales by 2030
Key Points
- Interested in Basf Se? Here are five stocks we like better.
- BASF’s new Zhanjiang Verbund site in Guangdong has started operations on schedule and below budget, marking the company’s
Wall Street Analysts See a 30.09% Upside in Accelerant Holdings (ARX): Can the Stock Really Move This High?
Accelerant Holdings (ARX) closed the last trading session at $14.99, gaining 13.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
Wall Street Analysts Predict a 41.87% Upside in Veeva (VEEV): Here's What You Should Know
Veeva Systems (VEEV) closed the last trading session at $172.61, gaining 3.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Does TSS (TSSI) Have the Potential to Rally 29.52% as Wall Street Analysts Expect?
TSS Inc. (TSSI) closed the last trading session at $13.38, gaining 11.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a Bet
AbCellera Biologics Inc. (ABCL) closed the last trading session at $5.62, gaining 7.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set
Wall Street Analysts Predict a 46.47% Upside in Sprinklr (CXM): Here's What You Should Know
Shares of Sprinklr (CXM) have gained 0.9% over the past four weeks to close the last trading session at $5.38, but there could still be a solid upside left in the stock if short-term price targets
ALT and the Rise of Dual Agonists Targeting Liver Disease
Altimmune ALT is trying to ride a clear shift in liver drug development. Programs are increasingly designed to hit multiple pathways at once, rather than relying on a single lever like weight loss
How FIS and Fuse Are Targeting the Quiet Cost of Outdated Lending Tech
Fidelity National Information Services, Inc. FIS recently formed a strategic partnership with Fuse, a cloud-native loan origination platform, to build a modern end-to-end origination solution for
Wall Street Analysts See a 34.66% Upside in NetEase (NTES): Can the Stock Really Move This High?
Shares of NetEase (NTES) have gained 2.1% over the past four weeks to close the last trading session at $118.7, but there could still be a solid upside left in the stock if short-term price targets
Wall Street Analysts Think Samsara Inc. (IOT) Could Surge 28.21%: Read This Before Placing a Bet
Samsara Inc. (IOT) closed the last trading session at $34.06, gaining 17.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall